Wells Fargo’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-55,139
| Closed | -$618K | – | 6751 |
|
|
2017
Q3 | $618K | Sell |
55,139
-4,082
| -7% | -$45K | ﹤0.01% | 4193 |
|
|
2017
Q2 | $651K | Sell |
59,221
-122,271
| -67% | -$1.22M | ﹤0.01% | 4046 |
|
|
2017
Q1 | $1.78M | Buy |
181,492
+36,034
| +25% | +$360K | ﹤0.01% | 3304 |
|
|
2016
Q4 | $1.57M | Buy |
145,458
+125,406
| +625% | +$1.25M | ﹤0.01% | 3345 |
|
|
2016
Q3 | $206K | Sell |
20,052
-268
| -1% | -$2.92K | ﹤0.01% | 4473 |
|
|
2016
Q2 | $265K | Sell |
20,320
-3,795
| -16% | -$49.7K | ﹤0.01% | 4253 |
|
|
2016
Q1 | $265K | Buy |
24,115
+1,131
| +5% | +$10.1K | ﹤0.01% | 4237 |
|
|
2015
Q4 | $211K | Sell |
22,984
-36,131
| -61% | -$302K | ﹤0.01% | 4417 |
|
|
2015
Q3 | $410K | Sell |
59,115
-19,002
| -24% | -$163K | ﹤0.01% | 4070 |
|
|
2015
Q2 | $767K | Buy |
78,117
+20,288
| +35% | +$185K | ﹤0.01% | 3814 |
|
|
2015
Q1 | $512K | Buy |
57,829
+12,447
| +27% | +$99.1K | ﹤0.01% | 3932 |
|
|
2014
Q4 | $397K | Buy |
45,382
+18
| +0% | +$146 | ﹤0.01% | 4067 |
|
|
2014
Q3 | $313K | Sell |
45,364
-4,726
| -9% | -$28.3K | ﹤0.01% | 4144 |
|
|
2014
Q2 | $263K | Buy |
50,090
+5,046
| +11% | +$24.6K | ﹤0.01% | 4249 |
|
|
2014
Q1 | $205K | Hold |
45,044
| – | – | ﹤0.01% | 4321 |
|
|
2013
Q4 | $227K | Sell |
45,044
-25,278
| -36% | -$122K | ﹤0.01% | 4194 |
|
|
2013
Q3 | $356K | Sell |
70,322
-26,660
| -27% | -$148K | ﹤0.01% | 3916 |
|
|
2013
Q2 | $481K | Buy |
+96,982
| New | +$461K | ﹤0.01% | 3704 |
|
Wells Fargo's SCLN Position: Q4 2017 in Review
Wells Fargo sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 55,139 shares — an estimated $618K sold.
Wells Fargo first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $1.78M in Q1 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Wells Fargo reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Wells Fargo sold 55,139 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $618K.
- Wells Fargo first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Wells Fargo's Sciclone Pharmaceuticals Inc position peaked at $1.78M in Q1 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Wells Fargo's 13F filing for Q4 2017, filed 8 Feb 2018.